Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fentanyl TAIFUN for breakthrough cancer pain
2007-005393-31Phase 3Terminated
- Sponsor
- Akela Pharma Inc.
- Start
- Jun 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fentanyl in breakthrough cancer pain (BTcP) (2 arms), sponsored by Akela Pharma Inc. Primary endpoints: SPID30, Time to significant pain relief and 1 more. Started Jun 2008; status: terminated.
02
Drugs
fentanyl
03
Conditions
breakthrough cancer pain (BTcP)
Beyond the preview
Go deeper on 2007-005393-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-005393-31.